"Prurigo nodularis"

Dupilumab for treating moderate to severe prurigo nodularis Dupilumab for treating moderate to severe prurigo nodularis Technology appraisal guidance Published: 13 March 2024 www.nice.org.uk/guidance/ta955 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility The recommendations in this guidance represent health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dupilumab for treating moderate to severe prurigo nodularis (TA955)© NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

Dupilumab (Dupixent) in prurigo nodularis Prescrire IN ENGLISH - Spotlight ''Dupilumab (Dupixent°) in prurigo nodularis'', 1 July 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Advancing healthcare policy * Positions * Mediator other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dupilumab (Dupixent°) in prurigo nodularis SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives Dupilumab (Dupixent°) in prurigo nodularis Marketing Authorisations Dupilumab

Nemolizumab ilto (Nemluvio) - prurigo nodularis Drug Approval Package: NEMLUVIO * Skip to main content * Skip to FDA Search * Skip to footer links An official website of the United States governmentHere's how you know The .gov means it's official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site

Dupilumab (prurigo nodularis) ' Addendum to Project A23-24 1 Translation of addendum A23-82 Dupilumab (Prurigo nodularis) – Addendum zum Projekt A23-24 (Dossierbewertung). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (prurigo nodularis ) Addendum to Project A23-24 (dossier assessment)1 ADDENDUM Project: A23-82 Version: 1.0 Status: 14 September 2023 Addendum A23-82 Version 1.0 Dupilumab – Addendum to Project A23-24 14 September 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dupilumab (prurigo nodularis) – Addendum to Project A23

Dupilumab (prurigo nodularis) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dupilumab (Prurigo nodularis) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (prurigo nodularis) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-24 Version: 1.0 Status: 28 June 2023 Extract of dossier assessment A23-24 Version 1.0 Dupilumab ( prurigo nodularis) 28 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dupilumab

Technology Briefings Ruxolitinib cream for treating prurigo nodularis 28 JANUARY 2025 Ruxolitinib cream for treating prurigo nodularis Ruxolitinib cream is in clinical development for the treatment of prurigo nodularis (PN). PN is a chronic skin disorder in which people have firm, raised bumps on the skin known as nodules. These nodules are very itchy and scratching the affected skin can cause

Dupilumab (Dupixent) - prurigo nodularis 1 Published 12 February 2024 1 SMC2598 dupilumab 300 mg solution for injection in pre-filled syringe or pre-filled pen (Dupixent®) Sanofi 12 January 2024 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland . The advice is summarised as follows: ADVICE: following a full submission assessed under the orphan equivalent medicine process. dupilumab (Dupixent®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. In two double-blind, randomised, phase III studies, dupilumab treatment

Predictors of perceived stress, perceived stigmatization and body dysmorphia in patients with chronic prurigo/prurigo nodularis: results from an observational cross-sectional multicentre European Study in 17 countries. Anxiety, depression and suicidal ideation are frequent in patients with chronic prurigo (CPG). To analyze perceived stress, stigmatization, body dysmorphia, anxiety, depression

Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study. The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real-world settings. Patients with moderate-to-severe PN who initiated

Improvement of Prurigo Nodularis With Erenumab. This case report describes a patient in her 50s with prurigo nodularis and itch at the elbows, which spread to all extremities, the trunk, and genital area.

Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥13 years: efficacy and safety data from a phase II/III study. The biological therapy nemolizumab has been shown to improve the signs and symptoms of prurigo nodularis (PN) to a significantly greater extent than placebo over 16 weeks of treatment. We now report efficacy

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of nemolizumab followed by subcutaneous injections of 30 mg or 60 mg (depending on baseline weight) every 4 weeks for 16 weeks or matching placebo. The primary end points were an itch response (a reduction of ≥4 points on the Peak Pruritus Numerical Rating Scale [PP-NRS; scores range from 0 to 10, with higher scores indicating more severe itch

Validation of a scoring algorithm for the clinician-reported outcome tool 'prurigo activity and severity (PAS)' based on clinical studies of dupilumab in adults with prurigo Nodularis. Prurigo nodularis (PN) also known as chronic prurigo, is a chronic inflammatory skin disease characterized by intensely itchy nodules/lesions which occur due to intensive scratching. PN management is, in part

Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study. Prurigo nodularis (PN) presents with intensely itchy hard nodules. Despite being limited to the skin, PN was noted to be associated with systemic diseases including diabetes and chronic renal failure. In previous smaller retrospective studies, several cardiac and vascular diseases were found more frequently

Spatial mass cytometry-based single cell imaging reveals a disrupted epithelial-immune axis in prurigo nodularis. Prurigo nodularis (PN) is a chronic, inflammatory skin condition that disproportionately affects African Americans and features intensely pruritic, hyperkeratotic nodules on the extremities and trunk. PN is understudied compared to other inflammatory skin diseases, with the spatial organization of the cutaneous infiltrate in PN yet to be characterized. In this work, we employ spatial imaging mass cytometry to visualize prurigo nodularis lesional skin inflammation and architecture with single cell resolution through an unbiased machine learning approach. PN lesional skin has increased expression of caspase 3, NFkB, and pSTAT3 as compared to healthy skin. Keratinocytes in lesional skin

Prurigo Nodularis: New insights into pathogenesis and novel therapeutics. Prurigo nodularis (PN) is an inflammatory skin condition characterized by intensely pruritic nodules on the skin. PN patients suffer from an intractable itch-scratch cycle leading to impaired sleep, psychosocial distress, and a significant disruption in quality of life. The pathogenesis of PN is associated with immune

A randomized, double-blinded, vehicle-controlled clinical trial of topical cryosim-1, a synthetic TRPM8 agonist, in prurigo nodularis. Prurigo nodularis (PN) is an intensively pruritic skin disease that negatively influences quality of life. Cryosim-1 (Intrinsic IB Spot) is a synthetic, selective transient receptor potential melastatin 8 agonist. To investigate the efficacy and safety of cryosim

Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis. Prurigo nodularis (PN) is characterized by intensely itchy nodules/lesions and skin pain, which can have a substantial impact on health-related quality of life (HRQoL). Treatment benefits on such symptoms and impacts

Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis. Prurigo nodularis (PN) is an intensely pruritic, inflammatory skin disease with a poorly understood pathogenesis. We performed single-cell transcriptomic profiling of 28,695 lesional and non-lesional PN cells. Lesional PN has increased dysregulated fibroblasts (FBs) and myofibroblasts. FBs

Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years. Prurigo nodularis, a chronic inflammatory skin condition, adversely affects the quality of life of affected individuals. Current treatment options for prurigo nodularis in Japan are limited . To evaluate the optimal dose, efficacy, and safety of long-term treatment with nemolizumab in patients with prurigo nodularis in Japan. In a 16-week, double-blind, phase II/III study, patients aged ≥13 years with prurigo nodularis were randomly assigned (1:1:1) to nemolizumab 30 mg, 60 mg, or placebo groups, with concomitant topical corticosteroids, every 4 weeks. The primary efficacy end point